| 摘要: |
| 目的:探讨多西环素用于8 岁以下儿童大环内酯类药物耐药肺炎支原体肺炎(MRMPP)的药学服务模式,评估其疗效与
安全性。方法:采用单臂、前瞻性观察性研究方法,纳入46 例8 岁以下使用多西环素的MRMPP 患儿,完成超说明书用药备案审
批,建立药师全程化药学服务,包括剂量规范、药学监护、用药教育及用药点评。分析患儿的疗效、不良反应和依从性。结果:46 例
患儿换用多西环素后,97. 8%(44/ 45,95%CI 88. 4%~99. 9%)的患儿治愈或好转。3 例(6. 5%,95%CI 1. 6% ~18. 4%)患儿发生
与多西环素相关的不良反应,主要表现为胃肠道反应和皮疹。用药教育满意率100. 0%(46/ 46,95%CI 92. 3% ~100. 0%),依从
性97. 8%(45/ 46,95%CI 88. 4%~99. 9%),超说明书用药点评合理率100. 0%(46/ 46,95%CI 92. 3% ~100. 0%)。结论:通过药
事管理与药师全程服务,多西环素用于8 岁以下儿童MRMPP 治疗显示出良好的疗效和可控的安全性。 |
| 关键词: 多西环素 超说明书用药 儿童 药学服务 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2026.11.005 |
|
| 基金项目:基金项目:江苏省药学会———奥赛康医院药学科研基金,编号A202429;江苏省药学会———恒瑞医院药学基金,编号H202313。 |
|
| Management of Off-Label Use of Doxycycline for Drug-Resistant Mycoplasma Pneumoniae Pneumonia inChildren Under 8 Years Old and Whole-Process Pharmaceutical Services |
| Duan Lufen, Yang Jingxia , Tang Lian |
| (The Affiliated Suzhou Hospital of Nanjing Medical University / Suzhou Municipal Hospital ,
Jiangsu Suzhou 215000, China) |
| Abstract: |
| Objective: To explore the pharmaceutical care model of doxycycline for macrolide-resistant Mycoplasma pneumoniae
pneumonia (MRMPP) in children under 8 years old, and to evaluate its efficacy and safety. Methods: A single-arm, prospective
observational study was conducted. A total of 46 children under 8 years old with MRMPP who received doxycycline were enrolled.
Off-label use registration and approval were completed, and comprehensive pharmaceutical care provided by clinical pharmacists was
established, including dose standardization, pharmaceutical monitoring, medication education, and prescription review. The efficacy,
adverse drug reactions, and compliance were analyzed. Results: After switching to doxycycline, 97. 8% (44/ 45, 95% CI 88. 4% to 99. 9%) of the children were cured or improved. Three children (6. 5%, 95% CI 1. 6% to 18. 4%) experienced adverse drug reactions
related to doxycycline, mainly manifesting as gastrointestinal symptoms and rash. The satisfaction rate with medication education was
100. 0% (46/ 46, 95% CI 92. 3% to 100. 0%), compliance was 97. 8% (45/ 46, 95% CI 88. 4% to 99. 9%), and the appropriate rate
of off-label prescription review was 100. 0% (46/ 46, 95% CI 92. 3% to 100. 0%). Conclusion: Under structured pharmaceutical
management and full-course pharmaceutical care, doxycycline demonstrates favorable efficacy and acceptable safety in the treatment of
MRMPP in children under 8 years. The established pharmaceutical care model provides a practical framework for managing off-label
drug use in pediatric populations. |
| Key words: doxycycline off-label drug use children pharmaceutical care |
